NCT02652624 - Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women | Biotech Hunter

Enrollment

472

Participants

Timeline

Start Date

February 19, 2016

Primary Completion Date

October 9, 2017

Study Completion Date

November 26, 2018

Conditions

HIV-1 Infection

Interventions

DRUG

E/C/F/TAF

150/150/200/10 mg FDC tablet administered orally once daily with food

DRUG

E/C/F/TDF

150/150/200/300 mg FDC administered orally once daily with food

DRUG

ATV

ATV 300 mg capsules administered orally once daily with food

DRUG

RTV

RTV 100 mg tablets administered orally once daily with food

DRUG

FTC/TDF

200/300 mg tablet administered orally once daily with food

DRUG

B/F/TAF

50/200/25 mg FDC tablet administered orally once daily without regard to food

Trial Locations (56)

6902

Stamford

10330

Bangkok

10400

Bangkok

10467

The Bronx

10514

Santo Domingo

10700

Bangkok

11000

Nonthaburi

11021

Great Neck

20009

Washington D.C.

20037

Washington D.C.

27710

Durham

28078

Huntersville

28207

Charlotte

30033

Decatur

30308

Atlanta

31201

Macon

31401

Savannah

33133

Miami

33136

Miami

33308

Fort Lauderdale

33401

West Palm Beach

33607

Tampa

33614

Tampa

34982

Ft. Pierce

40002

Khon Kaen

50200

Chiang Mai

63110

St Louis

75208

Dallas

75219

Dallas

76104

Fort Worth

77004

Houston

77401

Bellaire

78550

Harlingen

105275

Moscow

129110

Moscow

190020

Saint-Petersberg

190103

Saint Petersburg

191167

Saint Petersburg

196645

Saint Petersburg

350015

Krasnodar

394065

Voronezh

398043

Lipetsk

400010

Volgograd

603950

Nizhny Novgorod

620102

Yekaterinburg

630559

Koltsovo

656010

Barnaul

660049

Krasnoyarsk

664043

Irkutsk

680031

Khabarovsk

32803-1851

Orlando

01105

Springfield

07102

Newark

Unknown

Santo Domingo

Kampala

00909-1711

San Juan